BILIARY-EXCRETION OF REDUCED HALOPERIDOL GLUCURONIDE

被引:13
作者
EDDINGTON, ND [1 ]
YOUNG, D [1 ]
机构
[1] SCH PHARM BALTIMORE,DEPT PHARMACEUT,CLIN PHARMACOKINET LAB,20 N PINE ST,BALTIMORE,MD 21201
关键词
Biliary excretion; Glucuronide conjugates; Haloperidol; Reduced haloperidol;
D O I
10.1007/BF02245788
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The biliary excretion of haloperidol and reduced haloperidol were investigated in the guinea pig. Bile duct cannulated guinea pigs were administered a single intraperitoneal dose of haloperidol (1 mg/kg). Bile was continually collected over a 12-h period. Aliquots of the bile samples were analyzed by HPLC for free haloperidol and reduced haloperidol. The remaining portions of the bile samples were incubated with beta glucuronidase and reanalyzed for haloperidol and reduced haloperidol. Although no significant amount of haloperidol glucuronide was detected in the bile, a new metabolite of reduced haloperidol, reduced haloperidol glucuronide, was found. The amount of reduced haloperidol excreted in the bile as the glucuronide conjugate was significantly higher than the amount of haloperidol or reduced haloperidol. These results imply that reduced haloperidol glucuronide may play a role in the disposition of haloperidol and/or its metabolite, reduced haloperidol. © 1990 Springer-Verlag.
引用
收藏
页码:46 / 48
页数:3
相关论文
共 11 条
[1]  
ALTAMURA AC, 1987, LANCET, V1, P814
[2]  
BRAUN G. A., 1967, EUR J PHARMACOL, V1, P58, DOI 10.1016/0014-2999(67)90066-0
[3]  
EDDINGTON N, 1987, J PHARM SCI, V76, pS70
[4]   SENSITIVE ELECTROCHEMICAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ASSAY FOR THE SIMULTANEOUS DETERMINATION OF HALOPERIDOL AND REDUCED HALOPERIDOL [J].
EDDINGTON, ND ;
YOUNG, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (06) :541-543
[5]  
ERESHEFSKY L, 1984, J CLIN PSYCHOPHARM, V4, P138
[6]  
FORSMAN A, 1976, CURR THER RES CLIN E, V20, P319
[7]   REDUCED HALOPERIDOL - EFFECTS ON STRIATAL DOPAMINE METABOLISM AND CONVERSION TO HALOPERIDOL IN THE RAT [J].
KORPI, ER ;
WYATT, RJ .
PSYCHOPHARMACOLOGY, 1984, 83 (01) :34-37
[8]  
KORPI ER, 1985, ACTA PHARMACOL TOX, V56, P94
[9]  
MIDHA KK, 1987, J CLIN PSYCHOPHARM, V7, P362
[10]  
MIYAZAKI H, 1986, ARZNEIMITTEL-FORSCH, V36-1, P443